Search the database for deliberate release of GM medicinal products
Displaying 1 - 4 of 4
|EU record number
|Company / Sponsor
|Importation of doses of V920 for Emergency Use
|Merck Sharp & Dohme B.V.
|Recombinant Vesicular Stomatitis Virus (rVSV) in which the gene encoding for the VSV glycoprotein G has been deleted and replaced with the gene encoding the Zaire Ebola virus (ZEBOV) glycoprotein (GP).
|Only notified under the "contained use" procedure. Dossier submitted on 21/02/2018.
|Efficacy and safety of bilateral intravitreal injection of GS010: a randomized, double-masked, placebo-controlled trial in subjects affected with G11778A ND4 leber hereditary optic neuropathy for up to one year.
|human wild-type MT-NDA (mitochondrial NADH Dehydrogenase 4)
|Only notified under the "contained use" procedure. Dossier submitted on 22/03/2016.
|Phase I study to evaluate the safety and immunogenicity of a bivalent recombinant vaccine against human cytomegalovirus (HCMV).
|Hookipa Biotech AG
|Two replication-deficient lymphocytic choriomeningitidis virus (rLCMV) vectors, one expressing a truncated gBprotein of HCMV and one expressing the pp65 protein of the human CMV
|Only notified under the "contained use" procedure. Dossier submitted on 14/10/2015.
|A phase II, single-arm, multi-center trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
|Novartis Pharma Services AG
|Chimeric antigen receptor against CD19